Similar articles

• Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.

  Hurt AC, Ho HT, Barr I. Hurt AC, et al. Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. doi: 10.1586/14787210.4.5.795. Expert Rev Anti Infect Ther. 2006. PMID: 17140356 Review.
• Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.

  Watson KG, Cameron R, Fenton RJ, Gower D, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell D, MacDonald SJ, Mason AM, Nguyen V, Tucker SP, Wu WY. Watson KG, et al. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1589-92. doi: 10.1016/j.bmcl.2003.09.102. Bioorg Med Chem Lett. 2004. PMID: 15006410
• From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?

  Cheng CK, Tsai CH, Shie JJ, Fang JM. Cheng CK, et al. Future Med Chem. 2014 May;6(7):757-74. doi: 10.4155/fmc.14.30. Future Med Chem. 2014. PMID: 24941871 Review.
• Influenza--the case for combination therapy.

  Krystal MR, Meanwell NA. Krystal MR, et al. Curr Opin Investig Drugs. 2009 Aug;10(8):746-9. Curr Opin Investig Drugs. 2009. PMID: 19649919 No abstract available.
• [Targeted drugs against influenza--how will this affect the epidemics?].

  Pyhälä R, Ziegler T, Lumio J. Pyhälä R, et al. Duodecim. 2000;116(1):13-5. Duodecim. 2000. PMID: 11764456 Finnish. No abstract available.